Stromedix

Biomedical company focused on drugs for fibrosis, organ failure and cancer.

Launch date

2006

Employees

Market cap

Enterprise valuation

€68m (Public information from Feb 2014)

Cambridge Massachusetts (HQ)

Date	Investors	Amount	Round
Mar 2007	Atlas Venture Frazier Healthcare Partners	$1.0m	Series A
Apr 2008	Bessemer Venture Partners Atlas Venture New Leaf Venture Partners Red Abbey Venture Partners Frazier Healthcare Partners	$25.0m	Series B
Jan 2011	N/A	$2.0m	Series C
Feb 2014	Biogen	$75.0m Valuation: $75.0m	Acquisition
Total Funding		€25.5m

Recent News about Stromedix